Imatinib Koanaa (Imatinib)

Imatinib acts on malignant cells that depend on specific tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid‑tumor indications.

• Chronic Myeloid Leukemia (CML): improves survival by inhibiting the BCR‑ABL fusion protein that drives uncontrolled proliferation.
• Gastrointestinal Stromal Tumor (GIST): reduces tumor growth by blocking c‑KIT and PDGFR signaling.
• Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted cytotoxicity against BCR‑ABL‑positive lymphoblasts.

• Imatinib selectively binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts proliferative signaling, induces apoptosis in malignant cells, and limits angiogenesis, thereby controlling disease progression in cancers driven by these kinases.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Edema: swelling of the hands, feet, or periorbital area.
• Muscle cramps: intermittent tightness, often in the lower limbs.
• Fatigue: generalized tiredness not relieved by rest.
• Diarrhea: loose stools occurring intermittently.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Severe neutropenia: marked reduction in white blood cells increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury.
• Cardiac failure: signs of reduced cardiac output such as dyspnea.
• Pulmonary hypertension: elevated pressure in lung arteries causing breathlessness.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Before initiating Imatinib therapy, clinicians should evaluate baseline health status and monitor for potential complications.

• Blood count monitoring: perform complete blood counts regularly to detect neutropenia or anemia.
• Liver function assessment: check hepatic enzymes before and during treatment.
• Cardiac evaluation: assess baseline cardiac function, especially in patients with pre‑existing heart disease.
• Hypersensitivity screening: avoid use in individuals with known allergy to Imatinib or its excipients.
• Dose adjustment in hepatic impairment: consider reduced dosing for moderate to severe liver dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines through cytochrome‑P450 pathways and additive pharmacodynamic effects.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase Imatinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure.
• Antacids containing aluminum or magnesium: can impair oral absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: potential increase in serum digoxin concentrations.
• Diuretics (e.g., furosemide): may exacerbate fluid retention.
• Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): monitor for increased toxicity.
• QT‑prolonging agents (e.g., sotalol): observe cardiac rhythm for arrhythmias.